TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06656494: ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 266 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,413,720

Rescue Site Savings

+$942,480

Unlock Full NCT06656494 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06656494 Rescue Dossier →